Radboudumc
Jack Schalken serves as a Professor of Experimental Urology at Radboud University Medical Center since November 2001 and has been the Research Director of Urology at Radboud University Nijmegen Medical Centre since September 1986. A co-founder of NovioGendix, a biomarker discovery company, Jack Schalken held the position of Chief Scientific Officer from December 2006 to September 2015. Additionally, Jack Schalken was a Professor of Veterinary Oncology at the University of Utrecht from April 1996 to April 2002. Educationally, Jack Schalken earned a PhD in (Bio)chemistry and cancer research from Radboud University between 1977 and 1987.
This person is not in any teams
This person is not in any offices